Payment overview · 2025
General Payments
$651.28
31 reported records · 14 companies
Healthcare provider profile · identity verified
Erika Connor, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RANDOLPH, NY · NPI 1336136274
Verified facts
What the public records show
CMS Open Payments records show Erika Connor, M.D. received $651.28 in general payments during 2025 across 31 reported records.
Lilly USA, LLC accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $111.12 | 17.1% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $88.68 | 13.6% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $84.99 | 13.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $64.65 | 9.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $64.52 | 9.9% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $56.31 | 8.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.59 | 6.1% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.17 | 5.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.24 | 3.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.05 | 2.9% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.01 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.47 | 2.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.61 | 2.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.87 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $566.29 | 30 |
| Education | $84.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $88.68 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $64.52 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $61.35 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $56.31 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.09 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $49.77 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.35 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $39.59 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $35.17 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 92 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 143 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
92 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
80 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
143 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
110 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 667 | 145 |
| Omeprazole | Omeprazole | 473 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 460 | 55 |
| Lisinopril | Lisinopril | 453 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 407 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 386 | 73 |
| Gabapentin | Gabapentin | 356 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 76 |
| Ezetimibe | Ezetimibe | 340 | 73 |
| Meloxicam | Meloxicam | 339 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 264 | 43 |
| Famotidine | Famotidine | 243 | 43 |
| Furosemide | Furosemide | 243 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 42 |
| Sertraline Hcl | Sertraline Hcl | 220 | 40 |
| Losartan Potassium | Losartan Potassium | 205 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 205 | 40 |
| Spironolactone | Spironolactone | 197 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 196 | 23 |
| Simvastatin | Simvastatin | 183 | 46 |
| Metformin Hcl | Metformin Hcl | 181 | 38 |
| Azithromycin | Azithromycin | 156 | 88 |
| Fenofibrate | Fenofibrate | 155 | 30 |
| Jardiance | Empagliflozin | 143 | 28 |
| Allopurinol | Allopurinol | 139 | 26 |
| Raloxifene Hcl | Raloxifene Hcl | 132 | 26 |
| Trazodone Hcl | Trazodone Hcl | 131 | 23 |
| Alprazolam | Alprazolam | 124 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 123 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 30 |
| Potassium Chloride | Potassium Chloride | 114 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 113 | 24 |
| Eliquis | Apixaban | 110 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 27 |
| Carvedilol | Carvedilol | 103 | 16 |
| Tramadol Hcl | Tramadol Hcl | 102 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 25 |
| Atenolol | Atenolol | 97 | 24 |
| Mirtazapine | Mirtazapine | 93 | 13 |
| Farxiga | Dapagliflozin Propanediol | 92 | 16 |
| Montelukast Sodium | Montelukast Sodium | 90 | 18 |
| Fentanyl | Fentanyl | 88 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 88 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 81 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 78 | 14 |
| Metformin Hcl Er | Metformin Hcl | 77 | 18 |
| Entresto | Sacubitril/Valsartan | 73 | 11 |
| Lorazepam | Lorazepam | 71 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 69 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | suppressed |
| Methylprednisolone | Methylprednisolone | 67 | 40 |
| Xarelto | Rivaroxaban | 67 | 11 |
| Buspirone Hcl | Buspirone Hcl | 66 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 15 |
| Estradiol | Estradiol | 64 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 64 | suppressed |
| Bupropion Xl | Bupropion Hcl | 63 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 63 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 13 |
| Ibuprofen | Ibuprofen | 60 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 16 |
| Sucralfate | Sucralfate | 60 | suppressed |
| Topiramate | Topiramate | 59 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 59 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 21 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Mupirocin | Mupirocin | 54 | 20 |
| Donepezil Hcl | Donepezil Hcl | 51 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | suppressed |
| Cephalexin | Cephalexin | 50 | 28 |
| Morphine Sulfate Er | Morphine Sulfate | 50 | suppressed |
| Celecoxib | Celecoxib | 49 | suppressed |
| Lansoprazole | Lansoprazole | 49 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | suppressed |
| Prednisone | Prednisone | 48 | 17 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Rybelsus | Semaglutide | 44 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | 11 |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Bumetanide | Bumetanide | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Valsartan | Valsartan | 38 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Folic Acid | Folic Acid | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | 17 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 11 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Oxaprozin | Oxaprozin | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Nystatin | Nystatin | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 11 |
| Sulindac | Sulindac | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 16 |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 16 |
| Febuxostat | Febuxostat | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Prolia | Denosumab | 20 | 13 |
| Ramipril | Ramipril | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 12 |
| Felodipine Er | Felodipine | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Keppra | Levetiracetam | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Humira Pen | Adalimumab | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Norethindrone | Norethindrone | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $651.28 · 31 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, Fluad, Flucelvax, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, NUZYRA, OTEZLA, PREVNAR 20, REPATHA, TRELEGY ELLIPTA, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error